Skip to content

Pennant Group

US · PNTG #3029 by market cap Listed 1970
39.62 -0.34 -0.84%
Live - 5344 symbols - heartbeat 354s ago · 2026-10-07 19:54
After-hours 39.62 0.00%
Market cap
1.38B
P/B
3.85
EPS
0.84
Reader sentiment Are you bullish or bearish on PNTG?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 3.89 In line with history 63rd percentile
5-year average 3.87 · #27 of 40 in Medical Care Facilities
P/E ratio 43.91 In line with history 54th percentile
5-year average 64.43 · forward 27.71 · #26 of 30 in Medical Care Facilities
P/S ratio 1.27 Expensive vs history 74th percentile
5-year average 1.11 · forward 1.14 · #34 of 50 in Medical Care Facilities

Vs. peers Medical Care Facilities

Company Market cap P/E (TTM) P/B Div yield
Pennant Group (PNTG) 1.38B 43.54 3.85 0.00%
HCA Healthcare (HCA) 95.08B 14.73 -14.32 0.68%
Tenet Healthcare (THC) 20.92B 10.04 4.49 0.00%
Encompass Health (EHC) 12.08B 19.95 4.65 0.62%
DaVita (DVA) 11.28B 14.57 -14.74 0.00%
Fresenius Medical Care (FMS) 11.01B 11.14 0.78 4.13%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value35.11 Economic moatNone UncertaintyHigh

Trading 11.4% above Morningstar's fair value estimate.

Fair value

Pennant Group Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 14% premium over our quantitative fair value estimate of $35.11 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 26.3%, which sits in the bottom 30% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

The company's unfavorable dividend structure is an additional cause for concern. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, ranks in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.